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Renal transplantation and infection-focus on 
CMV 
V.C. Emery. Royal Free and Uniuersity College Medical School, London, 
UK 
CMV is a continuing cause of morbidity in the renal transplant 
recipient. As more high-risk transplantation is performed due to lack 
of suitably matched organs, the incidence of .CMV infection is 
increasing. My talk will focus on the insight that CMV load measures 
can provide in understanding the pathogenesis of CMV disease and 
the interrelationship between viral load in the blood and urine and 
established risk factors for CMV disease such as donodrecipient 
CMV serostatus, augmented immunosuppression, etc. A series of 
investigations in my laboratory has shown, using quantitative PCR 
methods, that CMV load is the most important parameter in CMV 
pathogenesis and accounts for the previous risk factors. The utility of 
these data in the context of antiviral intervention will then be 
discussed-how effective therapy needs to be to suppress replication 
and impact on disease, and the benefitddrawbacks of pre-emptive 
versus prophylactic regimens. I will conclude by discussing recent 
data implicating HHV-7 as a cofactor for CMV disease in renal 
transplant recipients and the possibility that controlled clinical trials 
aimed at inhibiting CMV replication may produce beneficial effects 
through inhibition of other beta-herpesviruses. 
ls247] Infections in ICU patients: focus on resistant 
bacteria 
J. Chastre. Rlanimation MtYicale, Hdpital Bichat, Paris, Frarice 
The importance of multiresistant microorganisms as a cause of 
nosocomial infection in ICU patients has been documented in many 
studies. By now, many Pseudumonar aeruginusa and .4cinetubacter 
baumannii strains are class I cephalosporinase producers and are 
resistant to piperacillin, aztreonam and ceftazidime. Klebsiella 
pneumoniae strains are also increasingly recognized as producers of 
transferable extended-spectrum beta-lactamases which confer resist- 
ance to third-generation cephalosporins. Other multiresistant aerobic 
Gram-negative bacilli include Xanthomonas (Stenotrophomunas) malto- 
philia and akcalkenes. Unfortunately, methicillin-resistant Staphylococcus 
aureus is also more and more frequently implicated as a causative 
pathogen in very sick patients who require ICU care for a long period 
of time. Therefore, the microbiological trends in nosocomial 
infection are evolving towards more resistant and more difficult-to- 
treat pathogens. A large body of evidence strongly supports the 
observation that the indiscriminate use of antimicrobial agents in 
ICU patients has immediate but also long-term consequences, 
contributing to the emergence of multiresistant pathogens and 
increasing the risk of serious superinfections. Virtually all reports 
emphasize that better antibiotic control programs In order to limit 
bacterial resistance are urgently needed in ICUs and that patients 
without true infection should not receive antimicrobial treatment. 
Therefore, it should be made clear to physicians confronted with 
ICU patients clinically suspected of having developed nosocomial 
infection that treating all these patients with new antimicrobial agents 
may lead to overtreatment in a large number of cases and, thus, to 
the rapid emergence of multiresistant pathogens not only in the 
treated patients but also in other patients hospitalized in the same 
m i  t . 
Pharrnacoeconornics in infectious diseases 
Is252J Outcome modeling in infectious diseases 
A. Brandt. Irrstitutefor Medical Infurmatics and Biustafistics, Riehen, 
Switzerland 
Medical economic evaluations have been performed for many 
pharmaceutical substances and immunization programs. Study results 
have helped to improve health policy decisions regarding preventive 
immunization and acute treatment. Disease models are used to 
estimate the medical outcomes and cost consequences of alternative 
intervention strategies, not just pharmaceutical treatments. Studies 
indicate that primary prevention is often more efficient in high-risk 
rather than low-risk populations and that secondary prevention tends 
to be more efficient than primary prevention. 
The evaluation of alternative antimicrobial treatments requires 
answers to a sequence of questions: Who needs treatment? How is 
the target population defined? What are the best treatments, doses, 
routes of administration, and duration of treatment? How can the 
expected long-term medical outcomes be estimated for a given target 
population, particularly in the face of only short-term evidence? 
What are the expected cost consequences of alternative treatments? 
Disease models attempt to represent disease processes, based on a 
synthesis of available medical data. They simulate the development of 
diseases for different patient populations under different management 
strategies: extrapolate short-term data and surrogate endpoints to 
long-term clinical outcomes; extrapolate from trial data to popu- 
lation (efficacy to effectiveness) in clinical practice; what-if analyses 
of different assumptions. Additionally, disease models allow us to 
determine the most important efficiency parameter as well as cost 
parameter by sensitivity analysis as well as to direct scarce resources 
to efficient treatments. 
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Infections by non-tuberculous mycobacteria 
J. Falkinham, L’irginia State University, Fralin Biotechnulugy Center, 
Blacksburg, 1.2, USA 
Non-tuberculous mycobacteria are opportunistic, intracellular 
pathogens whose source is environmental. Infection is associated with 
predisposing conditions: lung disease, alteration in chest architecture, 
or immune deficiency. Lung, skin, lymph node, gastrointestinal, 
disseminated and nosocomial infections have been reported. 
Examples of non-tuberculous mycobacteria causing pulmonary 
infections include Mycubacterium kansasii, M .  avium, M .  intracellulare, 
M. malmoenre and M .  xenopi. Though the epidemiologies of the 
infections differ, hf. marinum, M. haemophilnm and M.  ulcerans have 
all been implicated in skin infections. 111. auium is responsible cervical 
lymphadenitis in children. M. paratuberculosis causes diarrheal disease 
Uohne’s) in cattle and may be responsible for Crohn’s disease in 
humans. Although the majority of disseminated infections in AIDS 
patients are caused by M.  auium, other mycobacterial species, 
including M.  kansasii, Af. malmoense and newly identified species (e.g. 
M. genavense), are responsibie for infection as well. 
One source of non-tuberculous mycobacterial Infection is water. 
iLf. auiurn isolates from water have DNA fingerprints matching those 
of isolates from either human AIDS patients or SIV-infected monkeys 
who drank the water. Outbreaks of M. xenupi and M. ulerans have 
been associated, in time, with recovery from hot water systems or the 
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environment (respectively). Nosoconiial infections were associated 
with recovery of niycobacteria from sterile solutions. 
Non-tuberculoiis mycobacteria grow in natural and drinking 
waters and in phagocytic protozoa. Non-tuberculous niycobacteria 
utilize novel compounds for growth and grow over wide ranges of 
pH, temperature, and oxygen. Resistance to heavy metals and 
disinfectants coupled with biofilm formation ensure survival under 
adverse conditions. 
Pathogenesis and immunology of 
Mycobacterium avium infections 
S. Ehlers. h)rsrkunXs~entrirnr Burstel, b!fiktiolo,qie, Borsfcl, Gennany 
Granuloma formation is a hallmark of chronic mycobacterial 
infections. In inimunocompetent hosts, hl. avinni infection leads to 
circumscribed epithelioid granulomas that may riecrotize at their 
center, while in patients with AIDS, hf. avium-induced mononuclear 
lesions are composed of tissue-displacing sheets of foamy macro- 
phages. The u,e of selectively immunodeficient mice infected with 
hf. ~~rdutv has yielded important insights into the cellular and 
iiiolecular requirements of both the inflammatory response to 
infection and concomitant antibacterial effector functions. The 
virulence ofA2f. avinm strains may be assessed by their growth kinetics 
and induced organ pathology in susceptible mice. Strains of inter- 
mediate virulence are controlled by a CD4+ T-cell-mediated 
mechani~m involving IFN-gamma. T N F  may contribute to infection 
control, but is mostly necessary for maintaining granuloma integrity 
Nitric oxide plays no role in bacteriostasis o fh l .  avium, but modulate7 
iiiiniunopatholoby. IL-12 and GM-CSF may be most useful at 
reducing bacterial loads m conjunction with chemotherapy. Studies 
iii humms showed that genetic defects in IL-12, IL-12R or IFN- 
gamm.i-I< caii cause infcction with hi'. aiirrm to disseminate and that 
substitution inimunotherapy is helpful. In advanced HIV-1 disease, 
protease inhibitor therapy is the most effective means of containing 
hi'. at ium infection, although severe exacerbation of granulomatous 
inflamniation may complicate therapy As is true for tuberculosis, 
protection and pathology are closely associated in hl. atium infection, 
and imniunomodu~atory management of hyperinflammatory 
sequelae will become increasingly important. 
(s255( Clinical features and treatment of important 
non-tuberculous mycobacterial infections in 
HIV-negative patients 
I.A. Campbell. Llawcioqh Hospital, Card& L K  
Ilisease is caused mainly by hlycobacterium kansasii, hf. n v i m  complex 
(MAC), hl. ~~ialmornsc and hi'. xeriopi. Most patients are middle-aged, 
elderly nialec with pre-existmg lung disease. Symptoms and signs are 
noncpecific. Iiadiologic appearances are indistinbwishable from those 
of M .  tirhcrcitlnsis. 1)iagtiosi~ depends on  culture and cpecial methods 
of identification. 
For icI. kmrsasii, in vivo response correl.ites with recultc from 111 
vitro sensitivity testing, but for the other three cpccie\ clinical rec- 
ponse does not correlate with sensitivity/resictaiice tests pcrfbrmed 
in vitro against single drugs. 
Over 90% of patients with M.  kunsasii will be cured by 9 month\ 
of ethanibutol (E) and rifampicin (R). Death attributable to the 
organism occurs in 1% but 10-2546 will die within 5 year\. 
For hi. malnioense, MAC and Al. xcnopi, it is more difficult: 111 the 
recent large trial in the UK and Scandinavia, 32'W1 died within 5 years 
despite 2 years of RE or REH. In 5'% death was due to the organism. 
Thirty-two per cent were alive and cured at the end of 5 ycm,  while 
16% were treatment failures or relapsed. hl. S ~ W ~ J ~ I  WAS aswciated 
with the highect death rate (55%), whereas MAC war the moct 
difficult to eradicate. M .  nialnrornse responded better. The l3ritish 
Thoracic Society is testing the places of clarithroniycin, ciprofloxacin 
and hf. tarcac in a further multicenter trial. 
Treatment of non-tuberculous mycobacterium 
infections: standards and perspectives 
€3. Dautzenberg. Pnr.umt)loc~y Departmetif, Pirih-Solp?tri&e Hospital, 
Paris, Frurrcc 
The most common sources of non-tuberculou\ infection are Lif)m- 
bucteri~riir karisasii, hf. avinni and hf. xriiopi; other niycobc1ctcri.i x e  
involved in less than 10% ofmycobacterial infection case\. A ctmdard 
treatment is recommended for hl. kaiisasii: a combination of-rlfanipin 
(10 mg/kg), isoniazid (5 mg/kg) and ethanibutol (15-20 nig/kg). 
The initial phase ic 3 months. The  total duration reconimended, 
including the continuation phase, is usually 9 monthc. Three standard 
prophylactic regimens are recommended k x  121. m t m  prophylaxis in 
AIDS patient5 with low CD4 count: rifabutm, azithroniycm and 
clarithroniycin. Nevertheless, because of new antiviral therapy of 
AIDS, the number of cases of AIDS patients with low CIX counts 
is decreasing in developed countriey furthermore, pharmaceutical 
interactions with antiproteases are strong. Therefore, the rationale for 
diesemmated Af. a i i um prophylaxis is decreasing. N o  standard com- 
bination therapy hac been establiched for Al. m'1un1 disease, but 
according to avail~ble data, a combination of c~drlthromycin (or 
azithromycin), rifabutin and ethambutol (and ainikacin ac an option) 
could be recommended. The duration of treatment 15 ii\ually 1 ye.11- 
after culture conversion. For AIDS patients, pi-ophylaxir had to be 
initiated after the end of the curative phase oftreatment. No  stcmdard 
treatment was established for hl. xeimpi infection. In France, a 
combination of fluoroquinolone (sparfloxacin or ofloxacin), clarithro- 
niycin, rifabutin and ethanibutol is presented as the standard in AIDS 
and non-AIDS patients. To conclude, the standard treatment c o n -  
bination and duration remain to be ectabliyhed for non-tuberculou\ 
infections, but according to the best available data, provicional 
treatment for hl. avium and hl. xenupi could be recommended. 
